{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02287974",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CeTMMoTa/ICPDI/2010"
      },
      "Organization": {
        "OrgFullName": "Andalusian Network for Design and Translation of Advanced Therapies",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin",
      "OfficialTitle": "Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs: Study of the Needs of Insulin"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2018",
      "OverallStatus": "Terminated",
      "WhyStopped": "Patients' numebr randomized not achieved. Investigators team with lack of interest and commitment. The sponsor closed prematurely patients' recruitment.",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 25, 2013",
      "StudyFirstSubmitQCDate": "November 10, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 11, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 17, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 19, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Iniciativa Andaluza en Terapias Avanzadas",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To study the effect of the stem cells therapy autologous mononuclear from the bone marrow, autologous progenitor endothelial CD133 cells from the bone marrow and autologous mesenchymal stem cells from adipose tissue on the inflammatory cytokines, the resistance to insulin and the decrease of the needs of insulin, besides evaluates the safety, viability and efficiency of the intra-arterial infusion of stem cells in diabetic patients type 2 with CLI.",
      "DetailedDescription": "To study the effect of the stem cells therapy autologous mononuclear from the bone marrow, autologous progenitor endothelial CD133 cells from the bone marrow and autologous mesenchymal stem cells from adipose tissue on the inflammatory cytokines, the resistance to insulin and the decrease of the needs of insulin, besides evaluates the safety, viability and efficiency of the intra-arterial infusion of stem cells in diabetic patients type 2.\n\nDiabetic patients will include with critical ischemia chronicle of at least a low member limb (CLI) and without possibilities of revascularization. 48 evaluable patients will be included, of which 36 patients will be included in the experimental group (12 for every cellular group) and 12 in the group control by conventional treatment. The population to studying will be constituted by 48 evaluable patients."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Critical Limb Ischemia (CLI)"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous mononuclear stem cell from the bone marrow",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Stem cell infusion"
              ]
            }
          },
          {
            "ArmGroupLabel": "Autologous endothelial stem cell from the bone marrow",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Stem cell infusion"
              ]
            }
          },
          {
            "ArmGroupLabel": "Autologous mesenchymal stem cells from the adiposite tissue",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Stem cell infusion"
              ]
            }
          },
          {
            "ArmGroupLabel": "Current medication for the disease",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Current medication for the disease",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Stem cell infusion"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Stem cell infusion",
            "InterventionDescription": "Unique stem cell infusion of the randomized group",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous endothelial stem cell from the bone marrow",
                "Autologous mesenchymal stem cells from the adiposite tissue",
                "Autologous mononuclear stem cell from the bone marrow",
                "Current medication for the disease"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Serious Adverse Events",
            "PrimaryOutcomeDescription": "To evaluate the possible complications derived from the procedure (in the first 24 hours after the infusion of stem cells and the incident of Serious Adverse Events and not Serious Adverse Events related to the IMPD or to the procedure of administration",
            "PrimaryOutcomeTimeFrame": "the entire follow-up period, in the first 24 hours after the infusion of stem cells"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy measured by: The changes in the requirements of insulin, Peptide C, Resistance to the insulin, inflammatory Cytokines, pancreatic Reservation, Quantification of the degree of neovascularization (angio/arteriogenesis and vasculogenesis)",
            "SecondaryOutcomeDescription": "Efficacy measured by: The changes in the requirements of insulin, Peptide C, Resistance to the insulin, inflammatory Cytokines, pancreatic Reservation, Quantification of the degree of neovascularization (angio/arteriogenesis and vasculogenesis) after 6 months of the stem cells infusion",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge ≥18 and ≤ 85 years\nDiabetic type 2, in treatment with insulin at least 3 previous months.\nVascular disease infrapopliteal atherosclerotic of severe degree (Patients with category Rutherford-Becker ≥ 4), pretty or bilateral. The critical ischemia of the foot is defined as a persistent / persistent pain that needs analgesia and / or not healing present sores> 4 weeks, without evidence of improvement with conventional therapies and / or walking test between 1-6 minutes in two ergometries separated at least for 2 weeks and / or index ankle - arm in rest <0,8.\nImpossibility of revascularization surgical or endovascular or I fail in the surgery of revascularization performed at least 30 days before, with persistence or entry in phase of critical ischemia\nLife expectancy > 2 years.\nMajor amputation is not foreseen in any of the members in the next 6 months after the incorporation.\n\nNormal Biochemical and bone marrow parameters defined for:\n\nLeukocytes ≥ 3000\nNeutrophils ≥ 1500\nPlatelets ≥ 140000\nAST/ALT ≤ 2,5 standard range institution\nCreatinine ≤2,5 mg/dl and explanation of creatinine ≤ 30 ml/min (MDRD4)\nThe women in fertile age will have to obtain negative results in a pregnancy test realized in the moment of the incorporation in the study and promise to use a contraceptive method medically approved while the study lasts.\nPatients who give his Informed Consent in writing for the participation in the study. 10. Patients who have not taken part in another clinical trial in the last 3 months before the incorporation.\n\nExclusion Criteria:\n\nPrecedent of neoplasia or hematologic disease (disease myeloproliferative, syndrome myelodysplasic or leukaemia) in the last 2 years.\nMajor previous amputation.\nPatients with arterial uncontrolled hypertension (defined as arterial tension> 180/110 in more than one occasion).\nCardiac severe insufficiency (NYHA the IVth) or Fraction of Ejection of left ventricle (FAITH) lower than 30 %.\nPatients with ventricular malignant arrhythmias or unstable angina.\nDiagnosis of venous deep thrombosis in 3 previous months.\nPatients with genotype DD of the ECA or genotype E4 of the apo E.\nConcomitant therapy that includes oxygen hyperbaric, vasoactive substances, agents against angiogenesis or inhibiting Cox-II. The agents use is allowed antiplatelets.\nIndex of corporal mass> 40 Kg/m2.\nPatients with the diagnosis of alcoholism in the moment of the incorporation.\nProliferative Retinopathy without possibility of treatment.\nDiabetic Nephropathy with haemodialysis\nConcomitant disease that reduces the life expectancy to less than 1 years.\nImpossibility foreseen to obtain the inhaled one of 100ml of bone marrow.\nInfection for HIV, Hepatitis B or Hepatitis C.\nImpede in the follow-up.\nACV or heart attack of myocardium in the last 3 months\nAnaemia (Haemoglobin <7.9 g/dl)\nPatients before treated with cellular therapy.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Bernat Soria",
            "OverallOfficialAffiliation": "CABIMER (Centro Andaluz de Biología Molecular y Medicina Regenerativa)",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hopsital U. Virgen Macarena",
            "LocationCity": "Sevilla",
            "LocationState": "Seville",
            "LocationZip": "41007",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine)",
            "LocationCity": "Seville",
            "LocationZip": "41092",
            "LocationCountry": "Spain"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M9517",
            "InterventionBrowseLeafName": "Insulin",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M172956",
            "InterventionBrowseLeafName": "Insulin, Globin Zinc",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hypo",
            "InterventionBrowseBranchName": "Hypoglycemic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}